Cell Therapeutics Crushed

Cell Therapeutics ( CTIC) shares plunged early Monday after the biotech company reported disappointing clinical results for its cancer drug.

The Seattle-based company said a phase III study of its drug Xyotax in combination with carboplatin, known as Stellar 3, missed its primary endpoint in treating patients with nonsmall-cell lung cancer.

Cell Therapeutics had hoped the data would show its treatment was superior to standard chemotherapy.

"We are disappointed that Xyotax in combination with carboplatin showed equal efficacy after the unprecedented blended median and one-year survival we saw on the trial," the company said in a statement. "We are encouraged by the preliminary analysis, which demonstrates a significant Xyotax treatment effect, reduction in toxicities, and increased patient convenience."

In the premarket, shares were trading at $5.11, down $4.89, or almost 50%.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain